Role of Angiotensin II and Nitric Oxide in the Rat Paraventricular Nucleus

Eun-Kyoung Yang

Department of Physiology, School of Medicine, Kyungpook National University, Taegu 700-422, Korea

To investigate the mutual relationship between angiotensin II (Ang II) and nitric oxide (NO) in paraventricular nucleus (PVN), Ang II receptor type Ia (AT_{1A}), type Ib (AT_{1B}), endothelial constitutive nitric oxide synthase (ecNOS), and neuronal constitutive nitric oxide synthase (ncNOS) mRNA levels of rat PVN were measured after unilateral carotid artery ligation. AT_{1A} and AT_{1B} mRNA levels were markedly elevated 6 hrs after unilateral carotid artery ligation. Losartan injection ($10 \mu g/0.3 \mu l$) into the PVN augmented of the increment of AT_{1A} and AT_{1B} mRNAs It also increased ecNOS gene expression. In addition, AT_{1B} mRNA levels increased after N-nitro-L-arginine methyl ester (L-NAME) injection ($50 \mu g/0.3 \mu l$) into the PVN. These results suggest that Ang II and NO in the rat PVN may interplay, at least in part, through regulation of gene expression of ecNOS and AT_{1B}, respectively.

Key Words: Angiotensin II, Nitric oxide, Hypothalamic paraventricular nucleus, Rat, Angiotensin II AT₁ receptors (AT_{1A}, AT_{1B}), Nitric oxide synthase (ecNOS, ncNOS)

INTRODUCTION

The paraventricular nucleus (PVN) is an important integrative center for autonomic functions including regulation of cardiovascular activity (Dawson et al, 1998). The activity of PVN is affected either by autonomic projection from spinal cord, brainstem, and forebrain or by blood-born substances that gain access to the brain through circumventricular organs such as subfornical organ (SFO).

Angiotensin II (Ang II) is the main active component of the renin-angiotensin system. Two subtypes of Ang II receptors, AT₁ and AT₂, have been identified in the brain (Bottari et al, 1993). The AT₁ receptor is the predominant subtype found in the brain regions known to be affected by systemic Ang II, including PVN (Lebrun et al, 1995; Rowland et al, 1995) and SFO (McKinley et al, 1992; Lebrun et al, 1995; Rowland et al, 1995).

Recently, the brain is found to express higher levels of nitric oxide synthase (NOS) activity than any other

Corresponding to: Eun-Kyoung Yang, Department of Physiology, School of Medicine, Kyungpook National University, 101 Dong-in 2 Ga, Chung-Gu, Taegu 700-422, Korea. (Tel) 82-53-420-6927, (Fax) 82-53-424-3349, (E-mail) ekyang@knu.ac.kr

tissues (Millatt et al, 1999). Indeed, NOS expression has been identified in all areas of the brain, with neuronal constitutive NOS (ncNOS) and endothelial constitutive NOS (ecNOS) being the predominant isoforms under normal conditions. Within the cerebral circulation, NO generated by ecNOS acts as a vasodilator, and is believed to play a protective role in maintaining blood flow during cerebral ischemia (Huang et al, 1996). Several studies (McLay et al, 1995; Olson et al, 1997; Ackermann et al, 1998; Luvara et al, 1998) have shown a mutual relation between the renin-angiotensin and the NO-generating systems in various organs. Despite of several in vivo and in vitro evidences regarding the countervailing influences between Ang II and NO in the blood pressure control, renal function, and cellular proliferation, there is no direct evidence to date addressing the mutual relationship between Ang II and NO within PVN, one of the important brain region for cardiovascular regulation.

To address this question, the gene expression of AT_{1A} , AT_{1B} , ecNOS, and ncNOS in rat PVN were measured after unilateral carotid artery ligation. The results of present study show that losartan and N-nitro-L-arginine methyl ester (L-NAME) treatment upregulate ecNOS and AT_{1B} mRNA level, respectively.

42 EK Yang

METHODS

The experiments were performed using 10- to 12week-old male Sprague-Dawley rats. Under pentobarbital sodium (50 mg/Kg, i.p.) anesthesia, rat was placed on a stereotaxic device and a stainless steel guide cannula (27 guage) was placed into the PVN (1.0 mm lateral, 1.8 mm posterior to the bregma, and 5.0 mm below the skull surface). The injector extended 1 mm beyond the end of the guide cannula. Injection into the PVN was given in a $0.3 \mu l$ volume over 20 sec with the use of a 32-guage internal cannula. Thirty min after either losartan ($10 \mu g/0.3 \mu l$) or L-NAME $(50 \,\mu\text{g}/0.3 \,\mu\text{l})$ injection through PVN cannula, a tight ligature was applied around common carotid artery of male Sprague-Dawley rat. Booster of antagonist was injected through PVN cannula every 30 min during experiment. The rat was decapitated either 6 hrs or 18 hrs after operation. Based on previous studies (Finke et al, 1993; Mies, 1994), which have reported an isolation of RNA from formalin fixed tissue sufficient as a template for the reverse transcriptionpolymerase chain reaction (RT-PCR), rat was perfused with 10% formalin for verifying cannula placement. Hypothalamus was, then, rapidly dissected out, frozen in liquid nitrogen, and stored at -70° C until use.

Total RNA isolation

Total RNA was isolated according to the method described by Chomczynski & Sacchi (1987) with slight modifications. Frozen tissue was grounded to fine powder using the pestal and mortar in the presence of liquid nitrogen, and the denaturation solution (4 M guanidium thiocyanate, 25 mM sodium citrate pH 7, 0.5% sarcosyl, 0.2 M β -mercaptoethanol) was added (10 ml/g tissue). Homogenate was transferred to a fresh tube and 1/10 volume of 2 M sodium citrate (pH 4.0), 1 volume of water-saturated phenol and 1/5 volume of chloroform-isoamylalcohol (49:1) were sequentially added with gently mixing after each addition. The tube was kept on ice for 15 min and was centrifuged at 12,000 rpm for 15 min at 4°C. The upper aqueous phase was transferred to a fresh tube and reextracted with an equal volume of chloroformisoamylalcohol (49:1). The supernatant was collected and mixed with 2.5 volume of absolute ethanol, and then placed at -20° C for at least 1 hr. RNA was precipitated by centrifugation at 12,000 rpm for 15 min at 4°C. The pellet was washed in 75% ethanol. After drying in the air, RNA pellet was dissolved in DEPC-Q water and kept at -20°C until needed. The concentration and purity of RNA were determined by measuring the absorbance at 260 nm and 280 nm.

Reverse transcription PCR (RT-PCR)

The nucleotide sequence of the primers and references are presented in Table 1. Total RNA (20 µg) was primed with oligo (dT) primers, and first strand cDNA was synthesized using Moloney murine leukemia virus (MMLV) reverse transcriptase in a 30 μ l of reaction volume for 90 min at 37°C. The reaction mixture was heated for 5 min at 95°C to degrade template RNA and enzyme. In brief, 1 or $2 \mu l$ of each cDNA was amplified in a total volume of 25 μ l containing PCR buffer (10 X polymerase standard buffer plus 5 mM MgCl₂ and 0.1% formamide), 200 μ M of each dNTP, 20 pmole of each primers and 1.25 U of Taq DNA polymerase (Promega, USA). PCR was carried out using a Perkin-Elmer Cetus DNA Thermal Cycler as follows: 94°C for 45 sec, 58°C for 45 sec, 72°C for 1 min. PCR conditions are the same for all genes examined in this study except PCR cycles and the amount of template that were carefully selected according to the relative abundance of mRNAs in the PVN. After the end of PCR, one fifth of reaction mixture was separated on a 1.2% of agarose gel containing $0.5 \mu g/ml$ of ethidium bromide.

Densitometric analysis

The polaroid film was scanned using an Epson (ES-600) scanner with a resolution of 70 DPI (dot per inch) and 256 gray scale unit. In order to achieve a linear response curve, both brightness and contrast were finely tuned to the point where the gray scale unit of the background was within 20~40 and that of the darkest band was between 200~240. The resulting image was analysed from NIH-Image analysis program (written by Wayne Rasband, NIH, Betheda, MD). Using a selection box, the gray scale unit of various background areas was measured, subtracted from each band, and then, the mean density and total area of the band were calculated. The scale of each band was expressed by multiplying the mean density and the total area of the band. The resulting scale was used to quantify each band.

Gene	Primer sequence	Product size	Reference
ATIA	5' GCCTGCAAGTGAAGTGATTT 3' 5' TTTAACAGTGGCTTTGCTCC 3'	388 bp	Kitami et al, 1992
AT_{1B}	5' GCACACTGGCAATGTAATGC 3' 5' GTTGAACAGAAGAAGTGACC 3'	204 bp	Kitami et al, 1992
ecNOS	5' TACGGAGCAGCAAATCCAC 3' 5' GATCAAAGGACTGCAGCCTG 3'	591 bp	Ujiie et al, 1994
ncNOS	5' ATACCAGCCTGATCCATGGA 3' 5' CTCCAGGAGGGTGTCCAC 3'	540 bp	Bredt et al, 1991
GAPDH	5' ATCAAATGGGGTGATGCTGGTGCT3' 5' CAGGTTTCTCCAGGCGGCATGTCAG 3'	504 bp	Tso et al, 1985

Table 1. Primer sequences for AT1A, AT1B, ecNOS, ncNOS and GAPDH used in this study

Ang II receptor densities: receptor binding assay

Immediately after decapitation, hypothalamus was removed and homogenized in ice-cold Tric-HCl buffer (50 mM Tris, 1 mM EDTA, 150 mM NaCl, pH 7.2). After centrifugation at 600 g for 10 min, the supernatant was re-centrifuged at 48,000 g for 20 min. The supernatant was discarded and the pellet resuspended in Tris-HCl buffer. Total protein level of each homogenate preparation was determined in duplicate using the Bradford method and then diluted to a final concentration, $100 \mu g/100 \mu l$. For binding studies, hypothalamus tissue membranes, $100 \mu l$, were incubated with 400 μl incubation buffer (Tris-HCl buffer containing 1 mM bacitracin, 10 mM O-phenanthroline, 0.1% bovine serum albumin) containing 200 pM ¹²⁵I-Sar¹, Ile⁸-Ang II for 90 min at room temperature. Determinations were performed in triplicate. Non-specific, AT₁-specific, and AT₂ specific bindings were investigated in replicate tubes by co-incubation with $1 \mu M$ cold Ang II, $1 \mu M$ losartan, and 1 µM PD123319, respectively. All incubations were terminated by rapid filtration and washing with ice-cold Tris-HCl using a Brandel cell harvester and Whatman GF/B filters pre-soaked overnight in 1.5% BSA. Bound radioligand was quantified using a gamma counter (Beckmann, efficiency > 67%).

Statistical analysis

All data are presented as means \pm SE. Unpaired t-test was used for the comparison of means of dif-

Table 2. Changes in hypothalamic AT₁-specific density after carotid artery ligation

Group	% change in specific binding		
Sham	100.0 ± 15.2		
Unilateral + 6 hrs	75.8 ± 23.8		
Bilateral + 6 hrs	68.7 ± 18.2		
Unilateral + 18 hrs	115.8 ± 10.3		

Sham, unilateral, and bilateral denote sham-operated, unilateral and bilateral carotid artery ligated groups, respectively. Data represent a percentage compared to sham values. Values are mean \pm SE (n=6).

ferent groups. Differences were considered significant if p < 0.05.

RESULTS

The hypothalamic Ang II receptor density 6 hrs after either unilateral or bilateral carotid artery ligation decreased about 25 to 30% even though it failed to get statistical significance (Table 2). At this time, the ratio of AT₁/AT₂ was not different from that of sham-operated control, and AT₁ was the predominant subtype. Eighteen hrs after unilateral carotid artery ligation Ang II receptor density slightly increased compared to that of sham-operated control. In addition, AT₂ density was increased even though it was still lower




Fig. 1. The representitive ethidium bromide-staining gel of PCR products for AT_{1A} (A, top pannel), AT_{1B} (A, middle pannel), ecNOS (B, top left pannel), and ncNOS (B, top right pannel) in the hypothalamus from the rats 6 hrs after unilateral carotid artery ligation.





Fig. 2. Densitometric analysis of the PCR products for AT_{1A} and AT_{1B} corrected for GAPDH in each rat. The values were expressed in arbitary densitometric unit (A.D.U.). Sham, Cont, Los, L-NAME denote sham group and carotid artery ligated group without or with either losartan or L-NAME treatment, respectively. *<0.05, compared to sham values. *<0.05, compared to carotid artery ligated values without treatment (n=4 in each group).



After common carotid artery ligation, mRNA levels of AT_{1A} and AT_{1B} were increased compared to those of sham-operated control (Fig. 1 and Fig. 2). The treatment of losartan induced further elevation of AT_{1A} and AT_{1B} mRNA levels (Fig. 2). AT_{1B} gene expression was also increased by L-NAME treatment, but AT_{1A} mRNA level was not affected by L-NAME (Fig. 2). Losartan treat-




Fig. 3. Densitometric analysis of the PCR products for ecNOS and ncNOS corrected for GAPDH in each rat. The values were expressed in arbitary densitometric unit (A.D.U.). Sham, Cont, and Los denote sham group and carotid artery ligated group without or with losartan treatment, respectively. *<0.05, compared to sham values (n=4 in each group).

ment increased the gene expression of ecNOS profoundly, but it had no effects on gene expression of ncNOS following carotid artery ligation (Fig. 3).

DISCUSSION

The present study demonstrated that the receptor

density of AT₁ decreased and the gene expression of AT_{1A} and AT_{1B} of rat PVN increased 6 hrs after unilateral carotid artery ligation. In addition, the elevation of AT_{1B} mRNA levels was augmented by L-NAME treatment and the gene expression of ecNOS was increased by losartan treatment.

Both AT_{1A} and AT_{1B} mRNA levels were upregulated after carotid artery ligation. It might be a compensatory response to the decrease of AT₁ density by carotid artery ligation. Losartan treatment-induced augmentation of the increase of AT₁ mRNA level might also be due to the decrease of the number of active Ang II receptor by receptor blockade. L-NAME-induced upregulation of AT_{IB} mRNA levels in hypothalamus was well matched with previous reports (Ichiki et al, 1998; Usui et al, 1998), which were done in other tissues. The NO-induced decrease of Ang II receptors was first reported in rat vascular smooth muscle cells by Cahill et al (1995). Ichiki et al (1998) also demonstrated a profound inhibition of AT₁ receptor mRNA expression in vascular smooth muscle cells exposed to a NO donor. They showed that the inhibitory effect of NO on AT₁ expression might occur at the transcriptional level. However, the transcription factor(s) that mediate this effect remain to be identified. In the rat adrenal gland, one week-treatment with the NOS inhibitor L-NAME enhanced both the mRNA expression and the number of AT₁ receptors, but did not influence the AT₂ receptor number (Usui et al, 1998). In contrast, one-week L-NAME treatment increased the number of both AT1 and AT2 receptors in the rat heart, with both receptor subtypes returning to baseline levels after 4 weeks of L-NAME treatment (Katoh et al, 1998). Under this experimental condition, injection of L-NAME into the PVN augmented the gene expression of AT_{1B}, but not increased that of AT_{1A}. It therefore appears that NO may affect the expression of the Ang II receptor subtypes in a tissue specific manner.

The ecNOS mRNA level was increased by losartan treatment. Timmermanns et al (1993) demonstrated an evolving course dissociation of Ang II and glomerular receptor density. They suggested that the down regulation of receptor density may represent the elevation of Ang II and its augmented activity. Under present experimental conditions, AT₁ density showed a tendency to decrease 6 hrs after carotid artery ligation compared to that of sham-operated control. It is therefore, supposed to increase Ang II activity. Olson et al (1997) first demonstrated a stimulatory effect of Ang II on ecNOS mRNA, protein, and NO production

in cultured bovine pulmonary artery endothelial cells. They proposed that this effect might be a protective mechanism whereby lower pulmonary arterial pressure might be maintained in systemic hypertension. In Ang II infusion studies, Hennington et al (1998) reported that an acute infusion increased kidney ecNOS mRNA levels, but had no effect on ecNOS protein levels. Since this study was performed with whole-homogenized kidneys, the localization of these changes within the kidney remains to be determined. In addition, neither of these studies (Olson et al, 1997; Hennington et al, 1998) addressed the question of which Ang II receptor mediates the changes in ecNOS expression observed in response to Ang II. The results of the present study demonstrated that AT1 may be involved in the regulation of ecNOS gene expression after carotid artery ligation in rat PVN.

In conclusion, the present study has shown here that the AT_{1A} and AT_{1B} mRNA levels of rat PVN increased after unilateral carotid artery ligation. In addition, the gene expression of ecNOS was increased by losartan and the elevation of AT_{1B} mRNA level was augmented by L-NAME treatment. These results suggest that Ang II and NO in the rat PVN may interplay, at least in part, through regulation of gene expression of ecNOS and AT_{1B}, respectively.

ACKNOWLEDGEMENT

This work was supported by the Basic Medical Research Fund of Ministry of Education, Republic of Korea (KRF-97-021-F00024).

REFERENCES

Ackermann A, Fernandez-Alfonso MS, Sanchez de Rojas R, Ortega T, Paul M, Gonzalez C. Modulation of angiotensin-converting enzyme by nitric oxide. *Br J Pharmacol* 124: 291–298, 1998

Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. *Nature Lond* 351: 714-718, 1991

Bottari SP, de Gasparo M, Steckelings UM, Levens NR. Angiotensin II receptor subtypes: characterization, signaling mechanism, and possible physiological implications. *Front Neuroendocrinol* 14: 123-171, 1993

Cahill PA, Redmond EM, Foster C, Sitzmann JV. Nitric oxide regulates angiotensin II receptors in vascular smooth

46 EK Yang

muscle cells. Eur J Pharmacol 288: 219-229, 1995

- Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162: 156-159, 1987
- Dawson CA, Jhamandas JH, Krukoff TL. Activation by systemic angiotensin II of neurochemically identified neurons in rat hypothalamic paraventricular nucleus. *J Neuroendocrinol* 10: 453-459, 1998
- Finke J, Fritzen R, Ternes P, Lange W, Dolken G. A improved strategy and a useful housekeeping gene for RNA analysis from formalin fixed, paraffin embedded tissues by PCR. *Biotechniques* 14: 448-453, 1993
- Hennington BS, Dowds TA, Pino PA, Barry MT, Burke-Wolin T. ANG II stimulates synthesis of endothelial nitric oxide synthesis. *Hypertension* 31: 283–288, 1998
- Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. *J Cereb Blood Flow Metab* 16: 981 987, 1996
- Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, Takeshida A. Downregulation of angiotensin II type I receptor gene transcription by nitric oxide. *Hypertension* 31: 342-348, 1998
- Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H, Takeshita A. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Cir Res 83: 743-751, 1998
- Kitami Y, Okura T, Marumoto K, Wakamiya P, Hiwada K. Differential gene expression and regulation of typea angiotensin receptor subtypes in the rat. *Biochem Biophys Res Commun* 188: 446-452, 1992
- Lebrun CJ, Mollenhoff E, Bao G, Culman J, Unger T. Angiotensin II induces the expression of c-Fos mRNA in the central nervous system of the rat. *Clin Exp Hypertension* 17: 877 893, 1995
- Luvara G, Peuyo ME, Philippe M, Mandet C, Savoie F, Henrion D, Michel JB. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II anta-

- gonism. Arterioscler Thromb Vasc Biol 18: 1408-1416, 1998
- McKinley MJ, Badoer E, Oldfield BJ. Intravenous angiotensin II induces Fos-immunoreactivity in circumventricular organs of the lamina terminals. *Brain Res* 594: 295-300, 1992
- McLay JS, Chatterjee PK, Mistry SK, Weerakody RF, Jardine AG, McKay NG, Hawksworth GM. Atrial nitriuretic factor and angiotensin II stimulate nitric oxide release from human proximal tubular cells. *Clin Sci* 89: 527 531, 1995
- Mies C. A simple, rapid method for isolating RNA from paraffin-embedded tissues for reverse transcription-polymerase chain reaction (RT-PCR). *J Histochem Cytochem* 42: 811-813, 1994
- Millatt LJ, Abdel-Rahman EM, Siragy HM. Angiotensin II and nitric oxide: a question of balance. *Regul Peptides* 81: 1-10, 1999
- Olson SC, Dowds TA, Pino PA, Barry MT, Burke-Wolin T. ANG II stimulates endothelial nitric oxide synthase expression in bovine pulmonary artery endothelium. *Am J Physiol* 273: L315-L321, 1997
- Rowland NE, Li BH, Fregly MJ, Smith GC. Fos induced in brain of spontaneously hypertensive rats by angiotensin II and co-localization with AT-1 receptors. *Brain Res* 675: 127-134, 1995
- Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol Rev* 45: 205-251, 1993
- Tso JY, Sun XH, Kao TH, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene. *Nucleic Acids Res* 13: 2485-2502, 1985
- Usui M, Ichiki T, Katoh M, Egashira K, Takeshita A. Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. *Hypertension* 32: 527 533, 1998